Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Carcinoma

Interventions: Biological: Botulinum Toxin Type A
Other: Quality-of-Life Assessment
Procedure: Esophagectomy

First Posted Date: 2016-11-17

Last Posted Date: 2023-02-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 33

Registration Number: NCT02965976

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Phase 1

Suspended

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
PD-L1 Positive
Recurrent Head and Neck Squamous Cell Carcinoma
Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Advanced Squamous Non-Small Cell Lung Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Biological: Pembrolizumab
Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

First Posted Date: 2016-11-04

Last Posted Date: 2025-02-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 242

Registration Number: NCT02955290

Locations: 🇺🇸
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
St. Francis Hospital, Roslyn, New York, United States

and more 2 locations

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2

Completed

Conditions: Ovarian Serous Adenocarcinoma
BRCA1 Gene Mutation
BRCA2 Gene Mutation
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis
Drug: Olaparib
Biological: Tremelimumab

First Posted Date: 2016-11-02

Last Posted Date: 2024-11-19

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02953457

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
The Feinstein Institute for Medical Research/Lennox Hill Hospital, New York, New York, United States

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IV Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
EGFR Gene Mutation

Interventions: Other: Laboratory Biomarker Analysis
Biological: Nimotuzumab
Biological: Nivolumab

First Posted Date: 2016-10-27

Last Posted Date: 2023-10-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT02947386

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease
Muscle Weakness

Interventions: Dietary Supplement: Cholecalciferol
Dietary Supplement: Multivitamin
Other: Laboratory Biomarker Analysis
Other: Placebo
Other: Questionnaire Administration

First Posted Date: 2016-08-24

Last Posted Date: 2017-02-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT02877641

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

Not Applicable

Completed

Conditions: Stage IIC Skin Melanoma
Stage IIIA Skin Melanoma
Stage IIB Skin Melanoma
Stage IIIB Skin Melanoma
Stage IB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IIA Skin Melanoma

Interventions: Procedure: Diagnostic Microscopy
Drug: Fluorescein Sodium Injection
Other: Laboratory Biomarker Analysis
Procedure: Sentinel Lymph Node Biopsy

First Posted Date: 2016-08-05

Last Posted Date: 2022-08-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02857374

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Adenocarcinoma
Ovarian Mucinous Adenocarcinoma
Primary Peritoneal Serous Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-08-02

Last Posted Date: 2021-10-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02853318

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Withdrawn

Conditions: Stage IIA Fallopian Tube Cancer
Stage IIIB Ovarian Cancer
Stage IIIC Ovarian Cancer
Stage IIIA Fallopian Tube Cancer
Stage IIIA Primary Peritoneal Cancer
Stage IV Fallopian Tube Cancer
Recurrent Fallopian Tube Carcinoma
Stage IIIB Fallopian Tube Cancer
Stage IIIC Primary Peritoneal Cancer
Stage IV Primary Peritoneal Cancer

Interventions: Other: Laboratory Biomarker Analysis
Biological: Recombinant NY-ESO-1 Protein
Drug: Sirolimus

First Posted Date: 2016-07-14

Last Posted Date: 2018-05-01

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02833506

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Recurrent Colorectal Carcinoma
Stage IVB Colorectal Cancer
Stage IVA Colorectal Cancer

Interventions: Biological: Cetuximab
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-03-18

Last Posted Date: 2022-10-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02713373

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Phase 1

Active, not recruiting

Conditions: Metastatic Fallopian Tube Carcinoma
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Stage III Fallopian Tube Cancer AJCC v8
Stage IIIA Ovarian Cancer AJCC v8
Stage IIIB Primary Peritoneal Cancer AJCC v8
Stage IIIC Ovarian Cancer AJCC v8
Unresectable Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Metastatic Ovarian Carcinoma

Interventions: Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Decitabine
Procedure: Leukapheresis
Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes

First Posted Date: 2016-01-08

Last Posted Date: 2025-06-17

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT02650986

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy